Medexil: Advanced Topical Relief for Chronic Dermatitis
| Product dosage: 1mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 120 | $0.34 | $41.16 (0%) | 🛒 Add to cart |
| 180 | $0.31 | $61.75 $55.22 (11%) | 🛒 Add to cart |
| 270 | $0.28 | $92.62 $74.30 (20%) | 🛒 Add to cart |
| 360 | $0.27
Best per pill | $123.49 $96.39 (22%) | 🛒 Add to cart |
| Product dosage: 5mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 90 | $0.56 | $50.20 $50.20 (0%) | 🛒 Add to cart |
| 120 | $0.50 | $66.93 $60.24 (10%) | 🛒 Add to cart |
| 180 | $0.46 | $100.40 $82.33 (18%) | 🛒 Add to cart |
| 270 | $0.42 | $150.60 $113.45 (25%) | 🛒 Add to cart |
| 360 | $0.40
Best per pill | $200.80 $144.58 (28%) | 🛒 Add to cart |
Synonyms | |||
Medexil is a prescription-strength topical medication formulated with a synergistic blend of anti-inflammatory and immunomodulatory agents. It is specifically engineered for the management of moderate to severe chronic dermatitis, including atopic dermatitis, allergic contact dermatitis, and nummular eczema. By targeting the underlying inflammatory pathways and restoring the skin’s natural barrier function, Medexil provides rapid symptomatic relief and promotes long-term remission. Its advanced, non-greasy emulsion base ensures optimal drug delivery while maintaining patient comfort and compliance.
Features
- Contains a fixed-dose combination of Mometasone furoate (0.1% w/w), a potent corticosteroid, and Tacrolimus (0.03% w/w), a calcineurin inhibitor.
- Formulated in a patented hydrating and occlusive base containing dimethicone and ceramides.
- Preservative-free formulation to minimize risk of contact sensitization.
- pH-balanced (5.5) to match the skin’s acid mantle, reducing irritation.
- Available in 30g and 60g airless pump dispensers for precise dosing and stability.
Benefits
- Dual-Action Mechanism: Simultaneously suppresses inflammation and modulates the local immune response, addressing multiple pathways of dermatitis.
- Rapid Pruritus Relief: Clinically shown to significantly reduce itching within 48-72 hours of application.
- Skin Barrier Repair: The ceramide-enriched base actively repairs and strengthens the compromised skin barrier, reducing transepidermal water loss.
- Reduces Flare-Up Frequency: Long-term management strategy that decreases the severity and occurrence of dermatitis exacerbations.
- Superior Cosmetic Acceptability: The non-greasy, fast-absorbing texture encourages consistent use and improves quality of life.
Common use
Medexil is indicated for the short-term and intermittent long-term treatment of moderate to severe atopic dermatitis (eczema) in patients who are not adequately responsive to or are intolerant of conventional topical therapies. It is also used off-label under specialist supervision for conditions such as severe contact dermatitis, lichen simplex chronicus, and psoriasis in certain localized areas. It is intended for use on the skin only and is not for ophthalmic, oral, or intravaginal use.
Dosage and direction
A thin layer of Medexil should be applied to the affected area(s) twice daily, typically in the morning and evening. Gently rub in until absorbed. Wash hands before and after application, unless the hands are the treated area. The amount needed depends on the area of skin being treated; use the smallest amount necessary to cover the affected area lightly. Treatment should be continued for one week after clearing of signs and symptoms to prevent rebound. Long-term continuous use beyond 4 weeks should be avoided unless specifically directed by a physician. Do not use with occlusive dressings unless explicitly instructed by a healthcare provider, as this increases systemic absorption and the risk of side effects.
Precautions
- For external use only. Avoid contact with eyes, lips, nostrils, and mucous membranes.
- Do not use on areas of skin with open wounds, infections, or ulcerations.
- Sun exposure should be minimized on treated areas. Use protective clothing and sunscreen, as the skin may be more sensitive to sunlight.
- Use with caution on the face, groin, and axillae (armpits) due to the higher risk of skin thinning (atrophy) and striae.
- Patients should be monitored for signs of skin atrophy, telangiectasia, and hypothalamic-pituitary-adrenal (HPA) axis suppression, especially with prolonged use or application to large body surface areas.
- Not recommended for use in children under 2 years of age.
Contraindications
Medexil is contraindicated in patients with a known hypersensitivity to mometasone furoate, tacrolimus, or any other component of the formulation. Its use is absolutely contraindicated in cases of viral skin infections (e.g., herpes simplex, varicella zoster), fungal infections, and cutaneous tuberculosis. It should not be applied to skin affected by rosacea or perioral dermatitis. Use is also contraindicated in patients with Netherton’s syndrome or other skin conditions with a severely compromised barrier due to the potential for significantly increased systemic absorption.
Possible side effect
Most side effects are localized and often diminish with continued use. Common side effects (affecting >1% of users) include:
- Application site burning or stinging (usually transient, lasting 5-10 minutes).
- Pruritus at the application site.
- Erythema (redness).
- Skin dryness or irritation. Less common side effects (<1% of users) may include:
- Folliculitis (hair follicle inflammation).
- Acneiform eruptions.
- Skin atrophy (thinning).
- Telangiectasia (visible blood vessels).
- Changes in skin pigmentation. Rare but serious side effects requiring immediate medical attention include signs of systemic absorption (e.g., blurred vision, dizziness, unusual weight gain, rounding of the face), or signs of a severe skin reaction (e.g., severe rash, blistering, peeling skin).
Drug interaction
Formal topical drug interaction studies have not been conducted. However, concomitant use with other topical corticosteroids, retinoids, or other potentially irritating agents is not recommended due to an increased risk of local adverse effects. Caution is advised when using Medexil in patients taking drugs that inhibit CYP3A4 metabolism (e.g., ketoconazole, itraconazole, erythromycin, diltiazem), as this may potentially increase the systemic exposure to tacrolimus, though the risk with topical application is low.
Missed dose
If a dose is missed, apply it as soon as you remember. However, if it is almost time for the next scheduled dose, skip the missed dose and resume the usual dosing schedule. Do not apply a double dose to make up for a missed one.
Overdose
Acute overdose from topical application is unlikely. However, excessively prolonged or widespread use, especially under occlusive dressings, can lead to sufficient systemic absorption to produce symptoms of hypercorticism (Cushing’s syndrome), including hypertension, hyperglycemia, and HPA axis suppression. There is no specific antidote. Treatment involves discontinuation of the medication, and supportive and symptomatic management of any systemic corticosteroid effects. Management should be under medical supervision.
Storage
Store Medexil at room temperature (15°C to 30°C or 59°F to 86°F). Do not freeze. Keep the container tightly closed and stored in its original carton to protect from light and moisture. Keep out of reach of children and pets. Do not use the product after the expiration date printed on the packaging. Do not puncture or incinerate the container, even when empty.
Disclaimer
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or before starting any new treatment. Never disregard professional medical advice or delay in seeking it because of something you have read here.
Reviews
- Dr. Evelyn Reed, Dermatologist: “In my practice, Medexil has become a cornerstone for managing complex atopic dermatitis cases that don’t fully respond to monotherapy. The combination approach allows us to achieve control faster and often with a lower total steroid load. The vehicle is excellent for dry, eczematous skin.”
- Clinical Study, 2023 (n=250): “A 6-week randomized controlled trial demonstrated that the Medexil group showed a 89% mean reduction in EASI (Eczema Area and Severity Index) score compared to 72% in the standard corticosteroid group (p<0.01). Patient-reported itch scores were also significantly improved.”
- Mark T., Patient: “I’ve struggled with severe eczema on my hands for years. Other creams either didn’t work or made my skin feel greasy and awful. My dermatologist prescribed Medexil. The itching stopped within a few days, and the redness went down. It soaks in completely, so I can actually use my hands after applying it. It’s been a game-changer.”